TDS Pharm Co (XKRX:464280) EBIT : ₩5,791 Mil (TTM As of Dec. 2023)

View and export this data going back to 2024. Start your Free Trial

What is TDS Pharm Co EBIT?

TDS Pharm Co's earnings before interest and taxes (EBIT) for the three months ended in Dec. 2023 was ₩5,791 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2023 was ₩5,791 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. TDS Pharm Co's annualized ROC % for the quarter that ended in Dec. 2023 was 98.76%. TDS Pharm Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 164.69%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. TDS Pharm Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 12.24%.

TDS Pharm Co EBIT Historical Data

The historical data trend for TDS Pharm Co's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TDS Pharm Co EBIT Chart

TDS Pharm Co Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

EBIT

1,794.73

2,548.18

4,066.62

5,790.56

TDS Pharm Co Quarterly Data
	Dec20	Dec21	Dec22	Dec23
EBIT	1,794.73	2,548.18	4,066.62	5,790.56

Competitive Comparison of TDS Pharm Co's EBIT

For the Drug Manufacturers - General subindustry, TDS Pharm Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

TDS Pharm Co's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, TDS Pharm Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where TDS Pharm Co's EV-to-EBIT falls into.

TDS Pharm Co EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩5,791 Mil.

TDS Pharm Co (XKRX:464280) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

TDS Pharm Co's annualized ROC % for the quarter that ended in Dec. 2023 is calculated as:

	ROC % (Q: Dec. 2023 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2022 )	+	Invested Capital (Q: Dec. 2023 ))	/ count )
=	20065.66 * ( 1 - 14.6% )	/	( (18793.508	+	15907.376)	/ 2 )
=	17136.07364	/	17350.442
=	98.76 %

where

	Invested Capital		(Q: Dec. 2022 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	30468.621	-	3555.392	-	( 9937.115	-	max(0, 9830.052	-	17949.773	+	9937.115	))
=	18793.508

	Invested Capital		(Q: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	33970.008	-	3648.346	-	( 15136.063	-	max(0, 10065.351	-	24479.637	+	15136.063	))
=	15907.376

Note: The Operating Income data used here is four times the quarterly (Dec. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

TDS Pharm Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Dec. 2023 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Dec. 2022		Q: Dec. 2023
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	23162.236	/	( ( (9705.033 + max(4182.083, 0))	+	(8917.18 + max(5323.27, 0)) )	/	2 )
=	23162.236	/	( ( 13887.116	+	14240.45 )	/	2 )
=	23162.236	/	14063.783
=	164.69 %

where Working Capital is:

	Working Capital		(Q: Dec. 2022 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(5596.406	+	2162.636	+	150.891)	-	(3555.392	+	0	+	172.458)
=	4182.083

	Working Capital		(Q: Dec. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(6575.33	+	2492.868	+	44.679999999997)	-	(3648.346	+	0	+	141.262)
=	5323.27

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

TDS Pharm Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Dec. 2023 )
	=	5790.559	/	47306.512
	=	12.24 %

TDS Pharm Co EBIT Related Terms

Thank you for viewing the detailed overview of TDS Pharm Co's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

TDS Pharm Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » TDS Pharm Co Ltd (XKRX:464280) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

253 Pangyo-ro, Pangyo Inno Valley, Building C, Room 403, Bundang-gu, Gyeonggi-do, Seongnam-si, KOR, 13486

Website

https://www.tdspharm.com

TDS Pharm Co Ltd is engaged in the development and manufacturing of the Transdermal Drug Delivery System (TDDS), which is growing as a high-growth business sector in the field of drug delivery systems (DDS). The Transdermal Drug Delivery System (TDDS) is a drug delivery system that delivers drugs through the skin at a controlled speed. It has the advantages of increasing patient compliance with drugs, maximizing efficacy and effectiveness, such as minimizing side effects in the liver and digestive organs, controlling absorption rate, controlling discontinuation, controlling effective blood concentration, and enabling long-term continuous administration, and reducing burden compared to oral and injection drugs.

TDS Pharm Co Headlines

No Headlines